Please see MedTech Europe Update below, if your impacted by these changes please let me know at regulatory@bivda.org.uk
With this email, we would like to inform you about the latest chemicals developments at ECHA and kindly ask you to indicate if any of the following impacts your company by 24 September.
Please note that the substances highlighted in yellow are substances flagged as potentially in use by the sector
CLP
- Intentions to harmonise classification and labelling – link here:
- Swinglea Glutinosa extract (EC -, CAS -)
- N-ethyl-N-[2-[1-(2-methylpropoxy)ethoxy]ethyl]-4-(phenylazo)aniline (EC 252-021-1, CAS 34432-92-3)
Proposal to harmonise classification and labelling – link here:
-
- 1-isopropyl-2,2-dimethyltrimethylene diisobutyrate (EC 229-934-9, CAS 6846-50-0)
In addition, ECHA published the assessment of regulatory needs reports for the following substances:
We want to highlight that the latter includes formaldehyde (EC 200-001-8, CAS 50-00-0). The report concludes that currently there is no need for EU regulatory risk management for this substance, in light of the existing harmonised classification as Carc. 1. This substance was previously flagged by members for monitoring in anticipation of potential regulatory action; however, the ECHA report suggests such action is now unlikely.
